TYK2 and psoriasis: Unlike the TYK2/JAK1-selective brepocitinib, TYK2-selective deucravacitinib did not demonstrate a significant association with dyslipidemia in the psoriasis trial, indicating the potential improvement in the safety profile of TYK2-selective targeting [88].